Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cannabis Supplements’ Cancer Claims Spark FDA Warnings, Policy Point

This article was originally published in The Tan Sheet

Executive Summary

The level of agency concern about fraudulent claims made online for the products prompted warning letters from the compliance directors in the drug and food safety centers. FDA is “concerned at the proliferation of therapeutic claims being made about an increasing number” of hemp-based products.

You may also be interested in...



CDB Supplements Next On FDA's Investigational New Drug Warning List

The agency published warnings to four firms marketing supplements containing CDB ingredients with claims to treat or cure cancer made in statements including testimonials on their websites for products varying from oils, capsules, tinctures and lotions to snacks including gummies and lollipops.

Perrigo Reports Broad Growth, But Investors Sour On Turnaround's Price Tag

Its reported worldwide consumer Q4 net sales increased 12.7%, or 16.4% adjusted for currency exchange rates, product launches and other changes from the prior-year period, to $1.1bn. The s results, though, sent share price plummeting $8.64, more than 14%, to $51.82.

OTC Incontinence Device Ad Claims Sunk In UK, But US Label Claims Have FDA OK

UK ASA upholds complaints that questioned claims made in 2018 TV ads that Innovo was clinically proven to strengthen the pelvic floor and treat bladder weakness. In the US, however, claims Atlantic Therapeutics will use to promote OTC sales of Innovo were approved by FDA.

Topics

UsernamePublicRestriction

Register

PS107548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel